Call Options Transactions Made in Q4 2023 in Arbutus Biopharma Corp (ABUS)
This table provides information about the institutional ownership of Arbutus Biopharma Corp (ABUS) during Q4 2023. The information is specifically focused on institutions that hold call options of Arbutus Biopharma Corp.
Report Date | Institution (Fund) | Operation | Option | Shares change | Value Range | Shares Held | Trade History |
---|---|---|---|---|---|---|---|
Feb 09, 2024
Q4 2023
|
Citigroup Inc
|
BUY
|
CALL |
485K+ 249.28% |
$819K - $1.23M
|
679K
$2.68M
|
|
Feb 14, 2024
Q4 2023
|
Adar1 Capital Management, LLC
Austin, TX |
BUY
|
CALL |
178KNew |
$300K - $451K
|
178K
$700K
|
|
Feb 14, 2024
Q4 2023
|
Susquehanna International Group, LLP
Bala Cynwyd, PA |
BUY
|
CALL |
94.6K+ 132.49% |
$160K - $240K
|
166K
$654K
|
|
Feb 15, 2024
Q4 2023
|
Barclays PLC
London, X0 |
BUY
|
CALL |
75KNew |
$127K - $191K
|
75K
$296K
|
|
Feb 14, 2024
Q4 2023
|
Ken Griffin
Citadel Advisors LLC | Chicago, Il
|
BUY
|
CALL |
12.7K+ 13.2% |
$21.5K - $32.3K
|
109K
$429K
|
|
Feb 14, 2024
Q4 2023
|
Gts Securities LLC
New York, NY |
BUY
|
CALL |
5.9K+ 53.15% |
$9.97K - $15K
|
17K
$67K
|
|
Feb 14, 2024
Q4 2023
|
Centiva Capital, LP
New York, NY |
BUY
|
CALL |
3.6KNew |
$6.08K - $9.14K
|
3.6K
$14.2K
|